Manage episode 220676883 series 2394758
Why Alkermes once-promising depression drug failed to impress the FDA's advisory committee. Plus, how a $1.2 billion acquisition of Pacific Biosciences could move the needle at Illumina. Stocks: ALKS, ILMN, PACB
1322 episodes available. A new episode about every day averaging 33 mins duration .